Business Of Biotech

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse. Increased deal activity with Chinese biopharmaceutical companies is injecting new risk into traditional development models in the West, despite an uncertain policy environment in the U.S. vis-à-vis China. Will faster trial starts, cheaper asset upfronts, and a growing talent base slingshot Shanghai's biotech hub into an innovation destination on par with Boston and San Francisco?  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/?utm_source=Buzzsprout&utm_medium=BoB&utm_campaign=MSP_BoB]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On today's episode we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expertise. Other topics discussed include when to make at-risk investments ahead of clinical data, how to balance commercial growth with pipeline investment, the importance of financial planning during early product development stages, and how to manage expectations with a potential blockbuster product in the pipeline.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/?utm_source=Buzzsprout&utm_medium=BoB&utm_campaign=MSP_BoB]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted to investing over 15 years ago. Our conversation covers patent cliff implications, hot therapeutic areas and delivery mechanisms, geopolitical risks, alternative funding strategies, and private equity's move upstream to pre-clinical and pre-revenue biotech.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/?utm_source=Buzzsprout&utm_medium=BoB&utm_campaign=MSP_BoB]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year journey covering the pharmaceutical space, from Haymarket Media to PwC to Pharmaceutical Executive and InVivo magazines, before joining Life Science Connect as Chief Editor at Life Science Leader. He shares stories of the wild ride he's enjoyed along the way, how the stories he's covered have shaped his editorial perspective, and his plans for the next chapter of the Business of Biotech podcast.  Catch Ben's first episode as host next Monday, and every Monday after that. Subscribe to the podcast on your preferred platform and watch the videocast at lifescienceleader.com. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/?utm_source=Buzzsprout&utm_medium=BoB&utm_campaign=MSP_BoB]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission. It's a timely and important conversation that explores how these selective inhibitors could provide effective pain relief without the addiction risks and side effects of traditional opioids. In addition to the social and medical implications of Latigo's work, we discuss investor perceptions about pain management as a commercial opportunity and how Latigo is differentiating from traditional approaches by focusing on safety and tolerability rather than just efficacy The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com [https://urldefense.proofpoint.com/v2/url?u=https-3A__www.alston.com_&d=DwMFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=--yBBhBg30q4pEHDlugzFhyO5GMq27TcWBD6s3hVy30&m=C6ymsUhDiRNYXT-AnOLByEzDTBrTmqyB8X7D5XOfld5kSjUefQozx3QRHE9OqE9t&s=pnth6gr89aQC_1gdpFRmPamR3S7lDQtxQ2-Q8J8qyb8&e=]. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/?utm_source=Buzzsprout&utm_medium=BoB&utm_campaign=MSP_BoB]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]